GlassScriptPhysician profile
Gregory K Little
NPI 1003228438
$2,563.54
in general payments reported to CMS, 2019-2025
26 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $324 · 2021: $272 · 2022: $441 · 2023: $306 · 2024: $305 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $952.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $525.40 | 2021-2025 | |
| Pfizer INC. | $431.55 | 2019-2025 | |
| Amarin Pharma, INC. | $222.68 | 2019-2021 | |
| Lilly USA, LLC | $165.11 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $157.73 | 2020-2024 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.59 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $140.28 | 2019-2024 | Farxiga, Airsupra |
| Amgen INC. | $129.41 | 2019-2025 | Repatha, Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $129.10 | 2020-2023 | Xarelto |
| Astellas Pharma US INC | $58.62 | 2019-2023 | Veozah |
| Daiichi Sankyo INC. | $54.76 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $51.13 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Medline Industries LP | $42.89 | 2025 | |
| Novartis Pharmaceuticals Corporation | $42.72 | 2022 | |
| Dexcom, INC. | $38.62 | 2024 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $32.62 | 2024-2025 | Qelbree |
| Endogastric Solutions, INC | $30.00 | 2024 | Esophyx |
| Kowa Pharmaceuticals America, INC. | $23.92 | 2019 | |
| Horizon Therapeutics Plc | $20.58 | 2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $19.46 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.55 | 2023 | Xifaxan |
| Glaxosmithkline, LLC. | $17.34 | 2023 | Arexvy |
| Pulmonx Corporation | $16.26 | 2023 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Allergan, INC. | $15.55 | 2020 | |
| Melinta Therapeutics, LLC | $13.52 | 2021 | |
| Genentech USA, INC. | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Little listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.